1. Home
  2. HUIZ vs INAB Comparison

HUIZ vs INAB Comparison

Compare HUIZ & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huize Holding Limited

HUIZ

Huize Holding Limited

N/A

Current Price

$1.30

Market Cap

16.8M

Sector

Finance

ML Signal

N/A

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.39

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUIZ
INAB
Founded
2006
2016
Country
China
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.8M
13.7M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
HUIZ
INAB
Price
$1.30
$1.39
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$2.30
$6.00
AVG Volume (30 Days)
11.5K
34.4K
Earning Date
06-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.58
N/A
Revenue Next Year
$6.64
N/A
P/E Ratio
$7.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$1.17
52 Week High
$4.16
$2.73

Technical Indicators

Market Signals
Indicator
HUIZ
INAB
Relative Strength Index (RSI) 53.23 39.97
Support Level $1.19 $1.33
Resistance Level $1.55 $1.53
Average True Range (ATR) 0.07 0.08
MACD 0.02 -0.00
Stochastic Oscillator 87.97 27.99

Price Performance

Historical Comparison
HUIZ
INAB

About HUIZ Huize Holding Limited

Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: